Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry —Defining the “Goods” at Stake
AbstractCancer is a major burden on populations and health systems internationally. The development of innovative cancer medicines is seen as a significant part of the solution. These new cancer medicines are, however, expensive, leading to limited or delayed access and disagreements among stakeholders about which medicines to fund. There is no obvious resolution to these disagreements, with stakeholders holding firmly to divergent positions. Access to cancer medicines was recently explored in Australia in a Senate Inquiry into theAvailability of New, Innovative, and Specialist Cancer Drugs in Australia. We analysed the resultant Senate Report to identify competing stakeholder values. Our analysis illustrates that there are four main “goods” prioritized by different stakeholders: 1) innovation, 2) compassion, 3) equity, and 4) sustainability. We observe that, with the exception of sustainability, all of these “goods” put pressure on payers to provide access to cancer medicines more quickly and based on less rigorous eval uation processes. We then explore the consequences of giving in to such pressure and suggest that deconstructing the implicit values in calls for “enhanced access” to cancer medicines is necessary so that more nuanced solutions to the challenge of providing access to these high cost medicines ca n be found.
A new study finds that fecal hemoglobin can indicate more than an increased risk for colorectal cancer and is tied to an increased risk for all-cause mortality.Medscape Medical News
The F.D.A. announced that batches of a widely used generic drug, valsartan, made in China, might be tainted with a probable cancer-causing ingredient.
THE test for bowel cancer may also provide some insight into whether patients are at risk of other health problems, a study suggests. Detecting "hidden" blood in stool is a commonly used method for bowel cancer screening.
Newest Advances and Strategies in Prostate Cancer: Science and Stories on the Evolving Treatment Landscape and Implications for Patient Care
Germline BRCA mutations and other HR genes may offer biomarkers for response to this treatment.
The statement emphasizes strategies for multidisciplinary care, and proposes an algorithm for clinical management of bone metastasis in RCC.
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials, Published online: 17 July 2018; doi:10.1038/s41416-018-0165-zRelationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials
MicroRNAs (miRNAs) have emerged as crucial regulators of T lymphocyte survival, differentiation and function, all of which are key factors impacting the outcome of adoptive T cell-based immunotherapy. It has become increasingly clear that the adoptive transfer of memory CD8+ T cell subsets is highly correlated with objective clinical responses for patients with advanced cancer. However, it is unclear how to improve the long-term persistence of transferred CD8+ T cells using miRNAs. Here, we highlight the current advances in our understanding of the role of miRNAs in regulating the differentiation of memory CD8+ T cells. We...
Conclusions: Circulating HDL is significantly associated with treatment outcomes in patients with locoregionally advanced NPC. We suggest that HDL measurements will be of great clinical significance in the management of NPC.Cell Physiol Biochem 2018;48:285 –292
Dr. John Kisiel, MD, Mayo Clinic, talks Setting Specificity and Sensitivity for Tests | Involves recruiting up to 500 At-Risk Control Patients for DDW 2018 Author: Cancer-News Added: 07/16/2018